Ahmedabad based drug maker Zydus Cadila has recently acquired six brands from global pharma major MSD and its subsidiaries. The brands include Deca-durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range which fall in the men's health, women's health, cardiovascular and wound management therapy segments. MSD operates in areas including prescription medicines, vaccines, biologic therapies and animal health products and has presence across 140 countries.
The brands Deca-Durabolin and Durabolin are widely prescribed drugs for the treatment of osteoporosis, muscle wasting and management of negative nitrogen balance. Sustanon is a form of injectable testosterone in the men's health segment and is used as a testosterone replacement therapy by general practitioners, consultant physicians and andrologists.
The company said, "The deal includes transfer of distribution and commercialisation rights and assignment of trademarks of all the six brands to Zydus Healthcare Limited in India. Distribution and commercialisation rights for Deca-Durabolin and Durabolin has also been transferred to Zydus for Nepal as a part of the deal by Organon (India) Private Limited which is one of the legal subsidiaries through which MSD operates its business in India.
Speaking on the development, chairman of Zydus Healthcare Limited, Sharvil Patel said: "We have a long-standing association with MSD in India and value them as a partner. The brands with their strong equity are a perfect addition and complement our core business and brands. We look at this as a great opportunity to strengthen our core offerings to create value and growth."